Grant of Canadian Patent for OptiMAL

Fusion Antibodies PLC

09 September 2026

 

9 September 2026

Fusion Antibodies plc

("Fusion" or the "Company")

Grant of Canadian Patent for OptiMAL®

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company's patent application no. CA 3115150 (the "Patent") has been granted by the Canadian Intellectual Property Office (the "Canadian Patent Office"). The grant of the Patent follows the receipt of a notice of allowance in respect of the Patent from the Canadian Patent Office, details of which were announced by the Company on 22 June 2026.

The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The Patent is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.

The Company continues to progress additional patent applications in respect of the OptiMAL® Library in several other territories worldwide including Europe and China.

Enquiries: 

Fusion Antibodies plc	www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer	Via Walbrook PR
Allenby Capital Limited	Tel: [phone]
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)	Tel: [phone]
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]

Investor Hub                                                                                                      

We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/rJaa9e

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

 

END